Duloxetine: Clinical Overview
Duloxetine is a serotonin-norepinephrine reuptake inhibitor (SNRI) approved for major depressive disorder, generalized anxiety disorder, diabetic peripheral neuropathic pain, fibromyalgia, and chronic musculoskeletal pain, with a recommended starting dose of 30 mg once daily for one week, then 60 mg once daily for most indications.
Approved Indications
Duloxetine is FDA-approved for:
- Major depressive disorder (MDD) in adults 1
- Generalized anxiety disorder (GAD) in adults and children ≥7 years 1
- Diabetic peripheral neuropathic pain (DPNP) 2
- Fibromyalgia 1
- Chronic musculoskeletal pain 1
Note: Duloxetine is NOT approved for MDD in pediatric patients 1
Recommended Dosing
Adults
For most indications, start at 30 mg once daily for 1 week, then increase to 60 mg once daily 2. This titration strategy significantly reduces nausea, the most common adverse effect 2.
- Standard dose: 60 mg once daily (as effective as 60 mg twice daily) 2
- Maximum dose: 120 mg/day (60 mg twice daily) 2, 1
- Important: Doses above 60 mg/day for neuropathic pain are not recommended—they provide no additional efficacy and increase adverse effects 3
- Duration of adequate trial: 4 weeks at target dose 2
Pediatric Patients (GAD only, ages 7-17)
- Start: 30 mg once daily
- Increase to 60 mg once daily after 1 week
- Maximum: 120 mg/day 1
Administration
- Swallow capsules whole—do not chew, crush, open, or sprinkle contents 1
- May take with or without food 1
- If switching from another antidepressant, taper the initial medication first to avoid adverse effects 1
Contraindications and Precautions
Absolute Contraindications
- Concurrent use with MAOIs (allow 14-day washout) 1
- Concurrent use with thioridazine (risk of serious arrhythmias) 1
- Uncontrolled narrow-angle glaucoma 1
Use with Extreme Caution or Avoid
- Hepatic impairment: Avoid in any hepatic disease 1, 3
- Severe renal impairment: Avoid if CrCl <30 mL/min 1, 3
- Heavy alcohol use: Risk of severe liver injury 1
- Cardiac disease: Monitor blood pressure; venlafaxine may be preferred over duloxetine for cardiac patients 2
Drug Interactions
- CYP1A2 inhibitors (ciprofloxacin, enoxacin): Avoid combination 1, 4
- CYP2D6 substrates: Duloxetine inhibits CYP2D6; monitor drugs metabolized by this pathway 4
- Serotonergic drugs (SSRIs, SNRIs, triptans, tramadol, fentanyl): Risk of serotonin syndrome 1
- Anticoagulants/NSAIDs: Increased bleeding risk 1
Common Adverse Effects
Most Common (≥5% and twice placebo rate)
Adults:
- Nausea (most common reason for discontinuation) 5, 2
- Dry mouth
- Somnolence/fatigue
- Constipation
- Decreased appetite
- Increased sweating
- Dizziness 1
Pediatric patients (additional concerns):
- Decreased weight (14% vs 6% placebo) 1
- Vomiting
- Abdominal pain
- Monitor height and weight regularly in children 1
Serious Adverse Effects to Monitor
Suicidality: Black box warning—monitor closely, especially in patients <25 years and during initial treatment or dose changes 1
Hepatotoxicity: Watch for jaundice, dark urine, right upper quadrant pain, elevated liver enzymes 1
Blood pressure changes:
- Can increase blood pressure
- Can cause orthostatic hypotension and falls (especially elderly)
- Monitor BP before and during treatment 1
Serotonin syndrome: Agitation, hallucinations, tachycardia, hyperthermia, hyperreflexia, muscle rigidity—life-threatening 1
Abnormal bleeding: Increased risk, especially with concurrent anticoagulants/NSAIDs 1
Hyponatremia: Particularly in elderly patients 1
Urinary retention: Decreased urine flow or inability to void 1
Angle-closure glaucoma: Eye pain, vision changes, eye swelling/redness 1
Seizures: Risk increases with abrupt discontinuation 1
Discontinuation Syndrome
Never stop abruptly—taper gradually to avoid withdrawal symptoms including: dizziness, headache, nausea, irritability, insomnia, electric shock-like sensations, anxiety 1
Clinical Pearls
- Neuropathic pain: Duloxetine is a first-line agent for diabetic peripheral neuropathy with consistent efficacy 2. Pain relief can occur within one week at 60 mg/day 6
- Comorbid conditions: Excellent choice when depression/anxiety coexists with chronic pain, fibromyalgia, or diabetic neuropathy 3
- Glycemic control: No clinically significant effect on blood glucose in diabetic patients 3
- Cardiovascular safety: Unlike venlafaxine, duloxetine does not produce clinically important ECG changes or significant blood pressure increases in most patients 2
- Combination therapy: If inadequate response at 60 mg/day for neuropathic pain, add gabapentin or pregabalin rather than increasing duloxetine dose 3
- Aminotransferase monitoring: Not routinely necessary per recent reviews 2